Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors - Trial NCT06349837
Access comprehensive clinical trial information for NCT06349837 through Pure Global AI's free database. This Phase 1 trial is sponsored by Sichuan University and is currently Not yet recruiting. The study focuses on Solid Tumor. Target enrollment is 9 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sichuan University
Timeline & Enrollment
Phase 1
Apr 15, 2024
Mar 31, 2026
Primary Outcome
Dose Limiting Toxicities
Summary
This is a 3+3 dose escalation phase I study which aims to evaluate the safety and
 tolerability of low dose radiotherapy (LDRT) plus concurrent partial Stereotactic Ablative
 Radiotherapy (SBRT) and Tislelizumab in Patients with bulky tumors who have failed standard
 therapy. At least 9 participants will be enrolled in this study.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06349837
Non-Device Trial